NRX Pharmaceuticals, Inc. NRXP 深 滬
等待開盤 04-02 09:30:00 美东时间
2.16
+0.030
+1.41%
華盛通- 最 高2.24
- 今 開2.15
- 成交量 41.76万股
- 最 低 2.15
- 昨 收 2.13
- 總市值 7142.61万
- 52周最高 3.84
- 市盈率 靜 --
- 換手率 1.26%
- 52周最低 1.62
- 委 比 89.04%
- 總股本 3306.76万
- 歷史最高 769.90
- 量 比 0.38
- 振 幅 4.23%
- 歷史最低 1.58
- 每 手 1
- 風險率 0.52%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
03-25 10:31
BTIG Reiterates Buy on NRX Pharmaceuticals, Maintains $25 Price Target
BTIG analyst Thomas Shrader reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $25 price target.
03-25 00:27
NRX Pharmaceuticals Q4 EPS $0.20 Up From $(0.77) YoY, Sales $983.000K
NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly earnings of $0.20 per share. This is a 125.97 percent increase over losses of $(0.77) per share from the same period last year. The company reported $983.000 thousand
03-24 06:08
NRx Pharmaceuticals Intends To Submit New Drug Application For NRX-100 By June Following Successful Type-C FDA Guidance Meeting
NRXP has received confirmatory minutes from an in-person Type C guidance meeting at the headquarters of the US Food and Drug Administration. The meeting was attended by leaders of the FDA Division of Psychiatry Products,
03-16 19:11
美股大行评级 | 绩后暴跌超22%，MongoDB遭14家大行集团下调目标价；挪威邮轮、阿莎娜、Quantum Computing等也遭大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NRX Pharmaceuticals"买入"评级，目标价从40美元升至45美元；RBC Capital：维持NUVATION BIO"跑赢大市"评级，目标价从12美元升至13美元
03-04 10:22
HC Wainwright & Co. Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $45
HC Wainwright & Co. analyst Patrick R. Trucchio maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target from $40 to $45.
03-04 00:40
美股大行评级 | 潜在涨幅216.49%！杰富瑞上调BioAge Labs目标价至62美元，评级升至"买入"
今日重点评级关注：杰富瑞：上调BioAge Labs评级至"买入"，目标价从9美元升至62美元；RBC Capital：维持COMPASS Pathways Plc Sponsored ADR"跑赢大市"评级，目标价从21美元升至22美元
02-19 16:21
美股大行评级 | 潜在涨幅1226.53%！RenovoRx获Ascendiant Capital升目标价至13美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从12.5美元升至13美元；Lake Street：维持Insight Molecular"买入"评级，目标价从8美元升至12美元
02-18 16:48
D. Boral Capital Maintains Buy on NRX Pharmaceuticals, Maintains $34 Price Target
D. Boral Capital analyst Jason Kolbert maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $34 price target.
02-17 20:44
BRIEF-Nrx Pharmaceuticals (NasdaqNrxp) Announces Path To New Drug Application With Real World Data
BRIEF-Nrx Pharmaceuticals (NasdaqNrxp) Announces Path To New Drug Application With Real World Data Feb 17 (Reuters) - NRX Pharmaceuticals Inc NRXP.O : NRX PHARMACEUTICALS (NASDAQ:NRXP) ANNOUNCES PATH TO NEW DRUG APPLICATION WITH REAL WORLD DATA AND BROADER PROPOSED INDICATION FOR NRX-100 (KETAMINE)
02-17 20:28
